Advertisement

Recurrent Respiratory Papillomatosis and Human Papillomavirus

  • Frederik G. Dikkers
  • Robin E. A. Tjon Pian Gi
  • Michel R. M. San Giorgi
Chapter

Abstract

Recurrent respiratory papillomatosis (RRP) is a disease that is characterized by recurrent growth of exophytic wart-like lesions throughout the respiratory tract. The disease is mainly associated with low-risk human papillomavirus (HPV) types 6 and 11. The distribution of the age of onset of RRP shows three peaks: age 4 years old, age 34, and age 60–64. Patients with RRP generally experience voice problems and without treatment, eventually develop a compromised airway. Owing to the recurrent character of RRP, most patients require repeated surgical interventions to remove the lesions to keep the voice functional and the airway patent. There is currently no cure for RRP. This chapter reviews the etiology, diagnosis, therapeutic options, and prevention of RRP.

Keywords

Larynx Papilloma Papillomatosis Human papillomavirus Recurrent respiratory papillomatosis Microdebrider Cidofovir Bivalent HPV vaccine Cervarix® Quadrivalent HPV vaccine Gardasil® 

Notes

Acknowledgement

Note: this chapter is partly based on work done for the PhD theses of Dr. R.E.A. Tjon Pian Gi (Recurrent respiratory papillomatosis—from diagnosis to treatment. Rijksuniversiteit Groningen, the Netherlands, defended October 12, 2016) and Dr. M.R.M. San Giorgi (Recurrent Respiratory Papillomatosis—clinical course and psychosocial aspects. Rijksuniversiteit Groningen, the Netherlands, defended July 5, 2017).

References

  1. 1.
    Donne AJ, Clarke R. Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children. Int J STD AIDS. 2010;21(6):381–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Hawkes M, Campisi P, Zafar R, Punthakee X, Dupuis A, Forte V, et al. Time course of juvenile onset recurrent respiratory papillomatosis caused by human papillomavirus. Pediatr Infect Dis J. 2008;27(2):149–54.PubMedGoogle Scholar
  3. 3.
    Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008;118(7):1236–47.CrossRefPubMedGoogle Scholar
  4. 4.
    Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995;121(12):1386–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Tjon Pian Gi RE, San Giorgi MR, Slagter-Menkema L, van Hemel BM, van der Laan BF, van den Heuvel ER, et al. Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11. Head Neck. 2015;37(11):1625–32.CrossRefPubMedGoogle Scholar
  6. 6.
    Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2016;25:2–23.CrossRefGoogle Scholar
  8. 8.
    Bzhalava D, Eklund C, Dillner J. International standardization and classification of human papillomavirus types. Virology. 2015;476:341–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Hebner CM, Laimins LA. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol. 2006;16(2):83–97.CrossRefPubMedGoogle Scholar
  10. 10.
    Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–70.CrossRefPubMedGoogle Scholar
  11. 11.
    Omland T, Lie KA, Akre H, Sandlie LE, Jebsen P, Sandvik L, et al. Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia. PLoS One. 2014;9(6):e99114.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gerein V, Rastorguev E, Gerein J, Draf W, Schirren J. Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience. Otolaryngol Head Neck Surg. 2005;132(3):392–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Preuss SF, Klussmann JP, Jungehulsing M, Eckel HE, Guntinas-Lichius O, Damm M. Long-term results of surgical treatment for recurrent respiratory papillomatosis. Acta Otolaryngol. 2007;127(11):1196–201.CrossRefPubMedGoogle Scholar
  14. 14.
    Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4.CrossRefPubMedGoogle Scholar
  15. 15.
    zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Doorbar J. Latent papillomavirus infections and their regulation. Curr Opin Virol. 2013;3(4):416–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Campisi P, Hawkes M, Simpson K. Canadian Juvenile Onset Recurrent Respiratory Papillomatosis Working Group. The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope. 2010;120(6):1233–45.PubMedGoogle Scholar
  19. 19.
    Sanchez GI, Jaramillo R, Cuello G, Quintero K, Baena A, O’Byrne A, et al. Human papillomavirus genotype detection in recurrent respiratory papillomatosis (RRP) in Colombia. Head Neck. 2013;35(2):229–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Koskimaa HM, Waterboer T, Pawlita M, Grenman S, Syrjanen K, Syrjanen S. Human papillomavirus genotypes present in the oral mucosa of newborns and their concordance with maternal cervical human papillomavirus genotypes. J Pediatr. 2012;160(5):837–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Syrjanen S. Current concepts on human papillomavirus infections in children. APMIS. 2010;118(6-7):494–509.CrossRefPubMedGoogle Scholar
  22. 22.
    Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J. 1998;17(5):372–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Kashima HK, Shah F, Lyles A, Glackin R, Muhammad N, Turner L, et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope. 1992;102(1):9–13.CrossRefPubMedGoogle Scholar
  24. 24.
    Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol. 2003;101(4):645–52.PubMedGoogle Scholar
  25. 25.
    Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010;118(6-7):450–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012;30(Suppl 5):F34–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Ruiz R, Achlatis S, Verma A, et al. Risk factors for adult-onset recurrent respiratory papillomatosis. Laryngoscope. 2014;124:2338–44.CrossRefPubMedGoogle Scholar
  28. 28.
    Gerein V, Soldatski IL, Babkina N, Onufrieva EK, Barysik N, Pfister H. Children and partners of patients with recurrent respiratory papillomatosis have no evidence of the disease during long-term observation. Int J Pediatr Otorhinolaryngol. 2006;70(12):2061–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307(7):693–703.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Garcia-Pineres AJ, Hildesheim A, Herrero R, et al. Persistent human papillomavirus infection is associated with a generalized decreased in immune responsiveness in older women. Cancer Res. 2006;66:11070–6.CrossRefPubMedGoogle Scholar
  31. 31.
    San Giorgi MRM, van den Heuvel ER, Tjon Pian Gi RE, Brunings JW, Chirila M, Friedrich G, et al. Age of onset of recurrent respiratory papillomatosis: a distribution analysis. Clin Otolaryngol. 2016;41(5):448–53.CrossRefPubMedGoogle Scholar
  32. 32.
    Bonagura VR, Hatam LJ, Rosenthal DW, de Voti JA, Lam F, Steinberg BM, et al. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS. 2010;118(6-7):455–70.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Hatam LJ, Devoti JA, Rosenthal DW, Lam F, Abramson AL, Steinberg BM, et al. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression. Clin Cancer Res. 2012;18(7):1925–35.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Rosenthal DW, DeVoti JA, Steinberg BM, Abramson AL, Bonagura VR. T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis. Mol Med. 2012;18:1338–45.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope. 2001;111(1):57–69.CrossRefPubMedGoogle Scholar
  36. 36.
    Sajan JA, Kerschner JE, Merati AL, Osipov V, Szabo S, Blumin JH. Prevalence of dysplasia in juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2010;136(1):7–11.CrossRefPubMedGoogle Scholar
  37. 37.
    Kashima H, Mounts P, Leventhal B, Hruban RH. Sites of predilection in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 1993;102(8 Pt 1):580–3.CrossRefPubMedGoogle Scholar
  38. 38.
    Steinberg BM, Shikowitz M. Pediatric recurrent respiratory papillomatosis. In: Fried MP, Ferlito A, editors. The larynx. 3rd ed. San Diego: Plural Publishing; 2009. p. 539–62.Google Scholar
  39. 39.
    Omland T, Akre H, Vardal M, Brondbo K. Epidemiological aspects of recurrent respiratory papillomatosis: a population-based study. Laryngoscope. 2012;122(7):1595–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Buchinsky FJ, Donfack J, Derkay CS, Choi SS, Conley SF, Myer CM III, et al. Age of child, more than HPV type, is associated with clinical course in recurrent respiratory papillomatosis. PLoS One. 2008;3(5):e2263.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope. 2004;114(11 Pt 2 Suppl 104):1–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Seedat RY. The incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis in the Free State province of South Africa and Lesotho. Int J Pediatr Otorhinolaryngol. 2014;78(12):2113–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Derkay CS, Darrow DH. Recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2006;115(1):1–11.CrossRefPubMedGoogle Scholar
  44. 44.
    Gelinas JF, Manoukian J, Cote A. Lung involvement in juvenile onset recurrent respiratory papillomatosis: a systematic review of the literature. Int J Pediatr Otorhinolaryngol. 2008;72(4):433–52.CrossRefPubMedGoogle Scholar
  45. 45.
    Gabbott M, Cossart YE, Kan A, Konopka M, Chan R, Rose BR. Human papillomavirus and host variables as predictors of clinical course in patients with juvenile-onset recurrent respiratory papillomatosis. J Clin Microbiol. 1997;35(12):3098–103.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol. 2001;4(1):68–72.CrossRefPubMedGoogle Scholar
  47. 47.
    Rimell FL, Shoemaker DL, Pou AM, Jordan JA, Post JC, Ehrlich GD. Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors. Laryngoscope. 1997;107(7):915–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Padayachee A, Prescott CA. Relationship between the clinical course and HPV typing of recurrent laryngeal papillomatosis. The Red Cross War Memorial Children’s Hospital experience 1982–1988. Int J Pediatr Otorhinolaryngol. 1993;26(2):141–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Derkay CS, Hester RP, Burke B, Carron J, Lawson L. Analysis of a staging assessment system for prediction of surgical interval in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2004;68(12):1493–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Silverberg MJ, Thorsen P, Lindeberg H, Ahdieh-Grant L, Shah KV. Clinical course of recurrent respiratory papillomatosis in Danish children. Arch Otolaryngol Head Neck Surg. 2004;130(6):711–6.CrossRefPubMedGoogle Scholar
  51. 51.
    McKenna M, Brodsky L. Extraesophageal acid reflux and recurrent respiratory papilloma in children. Int J Pediatr Otorhinolaryngol. 2005;69(5):597–605.CrossRefPubMedGoogle Scholar
  52. 52.
    Robb PKJ, Weinberger PM, Perakis H, Li A, Klein AM, Johns MM III, et al. Association of asthma with clinically aggressive recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2011;137(4):368–72.CrossRefPubMedGoogle Scholar
  53. 53.
    San Giorgi MR, Helder HM, Lindeman RJ, de Bock GH, Dikkers FG. The association between gastroesophageal reflux disease and recurrent respiratory papillomatosis: a systematic review. Laryngoscope. 2016;126(10):2330–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Goon P, Sonnex C, Jani P, Stanley M, Sudhoff H. Recurrent respiratory papillomatosis: an overview of current thinking and treatment. Eur Arch Otorhinolaryngol. 2008;265(2):147–51.CrossRefPubMedGoogle Scholar
  55. 55.
    Niyibizi J, Rodier C, Wassef M, Trottier H. Risk factors for the development and severity of juvenile-onset recurrent respiratory papillomatosis: a systematic review. Int J Pediatr Otorhinolaryngol. 2014;78(2):186–97.CrossRefPubMedGoogle Scholar
  56. 56.
    Merrill RM, Roy N, Lowe J. Voice-related symptoms and their effects on quality of life. Ann Otol Rhinol Laryngol. 2013;122(6):404–11.CrossRefPubMedGoogle Scholar
  57. 57.
    Chadha NK, Allegro J, Barton M, Hawkes M, Harlock H, Campisi P. The quality of life and health utility burden of recurrent respiratory papillomatosis in children. Otolaryngol Head Neck Surg. 2010;143(5):685–90.CrossRefPubMedGoogle Scholar
  58. 58.
    Ilmarinen T, Nissila H, Rihkanen H, Roine RP, Pietarinen-Runtti P, Pitkaranta A, et al. Clinical features, health-related quality of life, and adult voice in juvenile-onset recurrent respiratory papillomatosis. Laryngoscope. 2011;121(4):846–51.CrossRefPubMedGoogle Scholar
  59. 59.
    Loizou C, Laurell G, Lindquist D, Olofsson K. Voice and quality of life in patients with recurrent respiratory papillomatosis in a northern Sweden cohort. Acta Otolaryngol. 2014;134(4):401–6.CrossRefPubMedGoogle Scholar
  60. 60.
    San Giorgi MR, Aaltonen LM, Rihkanen H, Tjon Pian Gi RE, van der Laan BF, Hoekstra-Weebers JE, et al. Quality of life of patients with recurrent respiratory papillomatosis. Laryngoscope. 2017;127(8):1826–31.CrossRefPubMedGoogle Scholar
  61. 61.
    San Giorgi MRM, Aaltonen LM, Rihkanen H, Tjon Pian Gi RE, van der Laan BF, Hoekstra-Weebers JE, et al. Validation of the distress thermometer and problem list in patients with recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 2017;156(1):180–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Lindman JP, Lewis LS, Accortt N, Wiatrak BJ. Use of the Pediatric Quality of Life Inventory to assess the health-related quality of life in children with recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2005;114(7):499–503.CrossRefPubMedGoogle Scholar
  63. 63.
    Ma X, Zhang J, Zhong W, Shu C, Wang F, Wen J, et al. The diagnostic role of a short screening tool—the distress thermometer: a meta-analysis. Support Care Cancer. 2014;22(7):1741–55.CrossRefPubMedGoogle Scholar
  64. 64.
    Donovan KA, Grassi L, McGinty HL, Jacobsen PB. Validation of the distress thermometer worldwide: state of the science. Psychooncology. 2014;23(3):241–50.CrossRefPubMedGoogle Scholar
  65. 65.
    San Giorgi MR, de Groot OS, Dikkers FG. Quality and readability assessment of websites related to recurrent respiratory papillomatosis. Laryngoscope. 2017;127(7):2293–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Tjon Pian Gi RE, Halmos GB, van Hemel BM, van den Heuvel ER, van der Laan BF, Plaat BE, et al. Narrow band imaging is a new technique in visualization of recurrent respiratory papillomatosis. Laryngoscope. 2012;122(8):1826–30.CrossRefPubMedGoogle Scholar
  67. 67.
    Dikkers FG. Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir—a prospective study. Eur Arch Otorhinolaryngol. 2006;263(5):440–3.CrossRefPubMedGoogle Scholar
  68. 68.
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.CrossRefPubMedGoogle Scholar
  69. 69.
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.CrossRefGoogle Scholar
  70. 70.
    Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87(7):544–7.CrossRefPubMedGoogle Scholar
  71. 71.
    Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. J Adolesc Health. 2011;49(5):467–75.CrossRefPubMedGoogle Scholar
  72. 72.
    Novakovic D, Cheng AT, Baguley K, Walker P, Harrison H, Soma M, et al. Juvenile recurrent respiratory papillomatosis: 10-year audit and Australian prevalence estimates. Laryngoscope. 2016;126(12):2827–32.CrossRefPubMedGoogle Scholar
  73. 73.
    Orji FT, Okorafor IA, Akpeh JO. Experience with recurrent respiratory papillomatosis in a developing country: impact of tracheostomy. World J Surg. 2013;37(2):339–43.CrossRefPubMedGoogle Scholar
  74. 74.
    FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;c3493:341.Google Scholar
  75. 75.
    Avelino MA, Zaiden TC, Gomes RO. Surgical treatment and adjuvant therapies of recurrent respiratory papillomatosis. Braz J Otorhinolaryngol. 2013;79(5):636–42.CrossRefPubMedGoogle Scholar
  76. 76.
    Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD, et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol. 2011;120(10):627–34.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Patel N, Rowe M, Tunkel D. Treatment of recurrent respiratory papillomatosis in children with the microdebrider. Ann Otol Rhinol Laryngol. 2003;112(1):7–10.CrossRefPubMedGoogle Scholar
  78. 78.
    Rees CJ, Postma GN, Koufman JA. Cost savings of unsedated office-based laser surgery for laryngeal papillomas. Ann Otol Rhinol Laryngol. 2007;116(1):45–8.CrossRefPubMedGoogle Scholar
  79. 79.
    Mohr M, Schliemann C, Biermann C, Schmidt LH, Kessler T, Schmidt J, et al. Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis. Oncol Lett. 2014;8(5):1912–8.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Tjon Pian Gi RE, Dietz A, Djukic V, Eckel HE, Friedrich G, Golusinski W, et al. Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide(R)). Eur Arch Otorhinolaryngol. 2012;269(2):361–2.CrossRefPubMedGoogle Scholar
  81. 81.
    Rogers DJ, Ojha S, Maurer R, Hartnick CJ. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg. 2013;139(5):496–501.CrossRefPubMedGoogle Scholar
  82. 82.
    Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2014;123(3):214–21.CrossRefPubMedGoogle Scholar
  83. 83.
    Zur KB, Fox E. Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child. Laryngoscope. 2017;127(7):1538–42.  https://doi.org/10.1002/lary.26450.CrossRefPubMedGoogle Scholar
  84. 84.
    Snoeck R, Andrei G, De Clercq E. Specific therapies for human papilloma virus infections. Curr Opin Infect Dis. 1998;11(6):733–7.CrossRefPubMedGoogle Scholar
  85. 85.
    Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36(2):127–43.CrossRefPubMedGoogle Scholar
  86. 86.
    Tjon Pian Gi RE, Ilmarinen T, van den Heuvel ER, Aaltonen LM, Andersen J, Brunings JW, et al. Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients. Eur Arch Otorhinolaryngol. 2013;270(5):1679–87.CrossRefPubMedGoogle Scholar
  87. 87.
    Chadha NK, James A. Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev. 2012;12:CD005053.PubMedGoogle Scholar
  88. 88.
    Forster G, Boltze C, Seidel J, Pawlita M, Muller A. Juvenile laryngeal papillomatosis—immunisation with the polyvalent vaccine gardasil. Laryngorhinootologie. 2008;87(11):796–9.CrossRefPubMedGoogle Scholar
  89. 89.
    Tjon Pian Gi RE, San Giorgi MR, Pawlita M, Michel A, van Hemel BM, Schuuring EM, et al. Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2016;273(10):3231–6.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2000;126(8):935–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Baio G, Capone A, Marcellusi A, Mennini FS, Favato G. Economic burden of human papillomavirus-related diseases in Italy. PLoS One. 2012;7(11):e49699.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Frederik G. Dikkers
    • 1
  • Robin E. A. Tjon Pian Gi
    • 2
  • Michel R. M. San Giorgi
    • 2
  1. 1.Department of Otorhinolaryngology, Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  2. 2.Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center GroningenUniversity of GroningenGroningenThe Netherlands

Personalised recommendations